{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:46Z","timestamp":1790732986947,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Classic Hodgkin lymphoma (cHL) is highly curable with risk-adapted first-line treatment. Due to exceptional efficacy, antiprogrammed cell death protein 1 antibodies (aPD1) are increasingly incorporated into first-line treatment. However, the short- and long-term immune-related adverse event burden in this setting is insufficiently understood. Here, we review the currently available evidence on the feasibility and safety of aPD1 first-line cHL treatment. A more harmonized and complete reporting is critical to enable a detailed understanding and comprehensive assessment of aPD1-related morbidity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029935","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:23:36Z","timestamp":1762017816000},"page":"3145-3152","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9338-2624","authenticated-orcid":false,"given":"Christian P.","family":"Jaworek","sequence":"first","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany"},{"name":"2German Hodgkin Study Group, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-9900","authenticated-orcid":false,"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany"},{"name":"2German Hodgkin Study Group, University of Cologne, Cologne, Germany"},{"name":"3Max Planck Institute for Biology of Ageing, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2025122511213749700_bib1","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2025122511213749700_bib2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"10450","key":"2025122511213749700_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"18","key":"2025122511213749700_bib4","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025122511213749700_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2025122511213749700_bib6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-025-01012-2","article-title":"Hodgkin lymphoma: great progress with room for improvement","volume":"22","author":"Br\u00f6ckelmann","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2025122511213749700_bib7","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025122511213749700_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.annonc.2024.12.009","article-title":"Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials","volume":"36","author":"Br\u00f6ckelmann","year":"2025","journal-title":"Ann Oncol"},{"issue":"11","key":"2025122511213749700_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41571-022-00685-3","article-title":"Mitigating acute chemotherapy-associated adverse events in patients with cancer","volume":"19","author":"Kuderer","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2025122511213749700_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","article-title":"Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship","volume":"20","author":"Lustberg","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2025122511213749700_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"2025122511213749700_bib12","doi-asserted-by":"crossref","first-page":"e2327145","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2025122511213749700_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"key":"2025122511213749700_bib14","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2025122511213749700_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2025122511213749700_bib16","doi-asserted-by":"crossref","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"2025122511213749700_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2025122511213749700_bib18","doi-asserted-by":"crossref","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2025122511213749700_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"2025122511213749700_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients' health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"2025122511213749700_bib21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"5","key":"2025122511213749700_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/thy.2021.0685","article-title":"Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's Thyroiditis","volume":"32","author":"Mosaferi","year":"2022","journal-title":"Thyroid"},{"issue":"10","key":"2025122511213749700_bib28","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2025122511213749700_bib41","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2025122511213749700_bib29","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"2025122511213749700_bib42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group Phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025122511213749700_bib43","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood-2023-188734","article-title":"Quality of life with nivolumab and AVD first-line treatment in Hodgkin lymphoma: patient-reported outcomes from the phase II GHSG Nivahl trial [abstract]","volume":"142","author":"Br\u00f6ckelmann","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"2025122511213749700_bib27","doi-asserted-by":"crossref","first-page":"e691267e","DOI":"10.1097\/01.HS9.0000971160.69126.7e","article-title":"P1066: pembrolizumab monotherapy as a first therapy for Hodgkin Lymphoma is deliverable in older or ABVD ineligible patients, does not preclude subsequent therapy, and provides adequate survival","volume":"7","author":"Dickinson","year":"2023","journal-title":"Hemasphere"},{"issue":"S2","key":"2025122511213749700_bib44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hon.3163_106","article-title":"Pembrolizumab as first therapy for Hodgkin Lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival","volume":"41","author":"Dickinson","year":"2023","journal-title":"Hematological Oncol"},{"key":"2025122511213749700_bib45","author":"Dickinson","year":"2023"},{"issue":"9","key":"2025122511213749700_bib24","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2025122511213749700_bib38","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"27","key":"2025122511213749700_bib40","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO-25-00204","article-title":"Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826","volume":"43","author":"Rutherford","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025122511213749700_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2021-147863","article-title":"Nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients: Niviniho, a Lysa phase II study [abstract]","volume":"138","author":"Lazarovici","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2025122511213749700_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"21","key":"2025122511213749700_bib26","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025122511213749700_bib33","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1182\/blood-2024-208412","article-title":"Potential delayed immune-related adverse events in patients treated with frontline pembrolizumab + AVD for classic Hodgkin lymphoma [abstract]","volume":"144","author":"Kuczmarski","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2025122511213749700_bib46","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025122511213749700_bib30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1200\/JCO-24-01278","article-title":"Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma","volume":"43","author":"Torka","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025122511213749700_bib31","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2352-3026(25)00051-1","article-title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","volume":"12","author":"Br\u00f6ckelmann","year":"2025","journal-title":"Lancet Haematol"},{"key":"2025122511213749700_bib32","doi-asserted-by":"crossref","first-page":"110776","DOI":"10.1016\/j.diabres.2023.110776","article-title":"Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - a comprehensive cancer center experience","volume":"202","author":"Zhang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"2025122511213749700_bib34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(25)00262-1","article-title":"Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial","volume":"26","author":"Ferdinandus","year":"2025","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2025122511213749700_bib35","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1182\/blood-2023-189250","article-title":"Fertility and gonadal function after first-line treatment with nivolumab-AVD in Hodgkin lymphoma patients: an analysis from the phase II GHSG Nivahl trial [abstract]","volume":"142","author":"Br\u00f6ckelmann","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025122511213749700_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"issue":"2","key":"2025122511213749700_bib37","doi-asserted-by":"crossref","first-page":"e002220","DOI":"10.1136\/jitc-2020-002220","article-title":"Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology","volume":"9","author":"\u00d6zdemir","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"2025122511213749700_bib39","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2024-207946","article-title":"PET-guided Brecadd in older patients with advanced-stage classic Hodgkin lymphoma: results of the phase 2 part of the GHSG HD21 trial [abstract]","volume":"144","author":"Ferdinandus","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/26\/3145\/2477514\/blood_bld-2025-029935-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/26\/3145\/2477514\/blood_bld-2025-029935-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T16:21:48Z","timestamp":1766679708000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/26\/3145\/548014\/Feasibility-and-safety-of-anti-PD1-first-line"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":46,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025,12,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029935","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,25]]},"published":{"date-parts":[[2025,12,25]]}}}